全球DNA 编码图书馆市场估计价值 2024年0.8亿美元 预计将达到 5.10亿美元到2031年以复合年增长率增长(CAGR),从2024年到2031年占16%.。 。 。 过去几年来,由于对药物研发的投资不断增加,以及制药公司越来越多地采用DNA编码图书馆来加快药物发现过程,DNA编码图书馆市场出现了显著增长。

由于基因组学和生物技术部门的投资增加,DNA编码图书馆市场预计将在预测期间迅速增长。 DNA编码库已作为一种创新技术出现,能够迅速筛选大型化学空间,以便进行可能的命中识别。 许多大型制药公司正在大量投资开发专有DNA编码库,以筛选广阔的化学空间,并找出能够成为治疗或药物候选者的新小分子点击量. 与传统的高吞吐量筛选相比,DNA编码库的优势,如大规模复合物测试,快速命中识别和较低的成本,正在驱动制药公司的需求. 此外,预计在预测期间,开发更有效DNA编码技术的持续技术进步将进一步推动市场的发展。

市场驱动力 - 对复杂疾病创新疗法的需求增加

保健部门在不断演变,以应对复杂疾病日益严重的威胁。 传统的药物发现方法往往无法跟上新出现的疾病的步伐。 这在癌症、自体免疫障碍和罕见遗传疾病等病症的有效治疗选择上造成了巨大差距。 患者急需新的疗法,能够以更具体和更少的副作用针对根源。 DNA编码库已成为满足这一日益增长的需求的有希望的解决办法。

通过允许同时快速筛选数百万种类似药物的小分子,DNA编码库为研究人员提供了前所未有的实验吞吐量水平. 这加速了对以精确方式接触疾病目标的打击的发现. 研究人员现在可以评价整个生物途径的分子相互作用,而不是只注重单个蛋白质. 这种系统层面的方法为通过同时调整多个节点来解决复杂的多要素条件提供了新的机遇. DNA编码库还能够评价以前通过常规合成方法无法访问的化合物,扩大新处理方案的潜在化学空间。

临床医生、护理人员和病人倡导者积极开展运动,加快发展和批准先进治疗方法,提高效果和生活质量。 他们的声音有助于形成政策改革,增加公共和私营部门对创新研究的投资。 随着疾病继续蔓延到全世界越来越多的人口和克服传统药物,社会期望生物药品通过DNA编码图书馆等尖端战略上升并满足这一需要。 它们有效探索大量合成化合物和天然化合物的能力使它们处于下一代针对复杂疾病的精确医学努力的前列。 社会压力和科学前景的这种交织将继续推动更多地采用这一技术。

制药公司越来越多地采用DNA编码图书馆

由于许多主要药物每年都失去专利保护,制药业不断面临压力,需要补充不断减少的管道。 发展新疗法是一个资源密集型的过程,往往要花十年时间,成功的可能性极低。 公司热切希望整合新兴技术,以加快从目标识别到临床考生的旅程. DNA编码库正在引起业界玩家的强烈兴趣,因为他们具有独特的能力,能够快速生成高质量的铅分子,对抗挑战性的目标.

与依赖合成小分子集的常规高通量筛选技术相反,DNA编码库的灵活性允许平行探索指数化更大和更加多样化的化学空间. 制药研发中心能够以成本效益高的方式进行涉及数百万化合物的多用途实验。 最初的图书馆配置可能侧重于特权结构或类似天然产品的脚手架,以提高打击率,对抗困难的目标. DNA编码进一步使后期的复合优化和剖析直接在库格式本身内,而无需单独合成.

AstraZeneca,诺华,萨诺菲,扬森等主要角色已经开始建立内部DNA库并发展相关专业知识. 专门从事该技术的合同研究组织也看到药剂合作和外包项目激增。 随着时间的推移,DNA编码的图书馆筛选预计将成为早先纳入药物开发工作流程的标准第一通道评价战略。 超越简单目标参与的新兴应用现在涉及活体动物研究、生物标志分析和抗药性特征分析。 随着概念证明研究的成功建立现实世界的临床和商业验证,该行业的采用率随时会迅速加快。

市场挑战 -- -- 与开发和维护DNA编码库有关的高成本

目前全球DNA编码图书馆市场面临的主要挑战之一是与开发和维护DNA编码图书馆有关的高昂费用。 大规模建立DNA编码库需要对技术、基础设施和熟练人员进行大量投资。 开发DNA编码库的过程始于设计和合成大量化合物,然后通过化学结扎附在DNA标签上。 这种创造数百万至数十亿DNA编码分子的过程是复杂的,也是资源密集型的. 它涉及使用昂贵的DNA合成器,试剂和其他实验室设备. 随着时间的推移,维护和筛选DNA编码库也会导致持续成本。 由于图书馆用于化验和实验,一些分子可能会降解或丢失,需要补充或扩张. 图书馆也需要定期定性,以确保多样性和质量得到维护。 所有这些与长期开发、改进和保存DNA编码库有关的活动,使这个市场参与者付出了代价。 资本需求高是一个重大挑战,特别是对预算有限的小型公司和初创企业而言。 这一成本障碍有可能限制这一有希望技术的进一步创新和应用的增长。

市场机会-通过将人工智能和机器学习纳入DNA编码库的机会

全球DNA编码库市场的关键机会之一是通过人工智能和机器学习技术的更大整合. 随着DNA编码库数据集的大小和复杂性不断增长,有可能利用AI/ML帮助优化库和发现过程. AI/ML算法可用于从大量测序和筛选数据中获取洞察力。 它们可以帮助推荐新的化合物用于合成,完善库设计,以及预测生物相关分子. 随着吞吐量增加,AI/ML模型可能有助于对大型输出数据集进行自动化分析。 他们还可以在硅化物筛选中提供动力,提出分子进行实验验证. 制药公司也在探索使用AI/ML方法,如基因模型,提出全新的DNA编码库. 如果成功应用,AI/ML技术有可能提高图书馆设计和候选人选择的效率。 这将有助于加快发现时限和降低成本。 因此,增加AI/ML集成为DNA编码库市场提供了一个机会,可以加强从创建到下游应用的整个工作流程。

By Therapeutic Area - The Rising Prevalence of Cancer Drives the Growth of Oncological Disorders Segment

In terms of By Therapeutic Area, Oncological Disorders contributes the highest share of the market owning to the rising prevalence of various types of cancer globally. Cancer has become one of the leading causes of death worldwide with nearly 10 million deaths in 2020. The increasing incidence of cancer can be attributed to growing adoption of sedentary and unhealthy lifestyles, rising environmental pollution levels, and aging population. According to WHO, the number of new cancer cases is expected to rise by over 70% in the next couple of decades.

The surging cancer burden has significantly boosted research activities and investment into development of innovative oncology drugs. DNA encoded libraries have emerged as a powerful tool for accelerating cancer drug discovery by enabling high throughput screening of billions of compounds for potential drug candidates. Many pharmaceutical companies are incorporating DEL technologies into their R&D pipeline to identify novel targets and lead molecules. Furthermore, DNA encoded libraries also help in developing personalized therapy based on cancer subtype and genetic profile of patients. The growing demand for targeted and precision oncology treatment is fueling the adoption of DEL platforms among key end users.

By Library Type- Advancement of Oligonucleotide-based DEL Technology Dominates the Library Type Segment

In terms of By Library Type, Oligonucleotide-based DEL contributes the highest share of the market owing to its technological advantages over other approaches. Oligonucleotide libraries allow encoding of up to billions of small molecules like peptides or synthetic compounds into DNA sequences, thus enabling extensive screening through next generation sequencing techniques. Compared to other forms, oligo-DEL offers higher library complexity and diversity, better stability and storage capabilities. Continuous technological upgrades like development of longer and more stable DNA oligos have augmented the encoding capacity and screening efficiency of these libraries.

Rising investments by leading players to enhance oligonucleotide DEL platforms through automation, machine learning integration and cloud computing solutions have simplified the entire drug discovery workflow. This has increased the adoption of oligo-DEL among small biotech firms with limited R&D budgets. Moreover, extensive academic research has improved the molecular encoding, library synthesis, and data analytics methods used in oligonucleotide-based DEL systems. Wider availability of cost-effective commercial tools and reagents is also supporting the growth of this most advanced DEL technology.

By Application - Drug Discovery Emerges as the Dominant Application Driving DEL Market Growth

In terms of By Application, Drug Discovery contributes the highest share of the market owing to the critical role of DEL in facilitating early phase target identification and lead optimization process. DNA encoded libraries have revolutionized drug discovery approaches by enabling rapid screening of small molecule libraries against thousands of biological targets simultaneously. This has significantly accelerated the hit finding and lead generation compared to conventional high-throughput screening methods.

DEL platforms further aid in systematic exploration of structure-activity relationships and optimization of hit compounds into drug candidates. Their application helps unravel complex target-disease relationships and elucidate novel mechanisms of action. Furthermore, DNA encoded libraries also help expand the druggable target space by facilitating screening efforts against membrane proteins and other historically challenging targets. The ability to assay billions of compounds in parallel has enabled profiling of compounds against entire proteomes or genome-wide RNAi libraries at an unprecedented scale.

The improved efficiency, target coverage and data generation capabilities of DNA encoded libraries have led to their widespread adoption by pharmaceutical giants and biotech startups. Growing R&D investments and increasing focus on innovative drug discovery is expected to further propel the use of DEL technology across various stages of drug development process. This growing demand from drug developers globally makes drug discovery the principal application driving the entire DEL market.

在全球DNA编码库市场运营的主要角色包括NovAliX,PROVendis,SpiroChem,Vipergen,WuXi AppTec,X-Chem,Philochem AG,Philogen S.p.A,AstraZeneca,Amgen,Bristol-Myers Squibb,GSK(GlaxoSmithKline),Merck & Co.,Pfize和Roche.